Menu Search
Equities

Dizal Jiangsu Pharmaceutical Co Ltd

688192:SHH

Dizal Jiangsu Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)47.74
  • Today's Change0.42 / 0.89%
  • Shares traded6.24m
  • 1 Year change+7.50%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Dizal Jiangsu Pharmaceutical Co Ltd had net income fall 50.50% from a loss of 736.00m to a larger loss of 1.11bn despite a -- increase in revenues from 0.00 to 91.29m.
Gross margin97.17%
Net profit margin-238.28%
Operating margin-238.62%
Return on assets-56.00%
Return on equity-110.84%
Return on investment-83.89%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Dizal Jiangsu Pharmaceutical Co Ltd fell by 47.47m. However, Cash Flow from Investing totalled 611.19m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 967.88m for operations while cash generated from financing totalled 308.25m.
Cash flow per share--
Price/Cash flow per share--
Book value per share1.03
Tangible book value per share-0.0227
More ▼

Balance sheet in CNYView more

Dizal Jiangsu Pharmaceutical Co Ltd has a Debt to Total Capital ratio of 67.40%, a higher figure than the previous year's 4.60%.
Current ratio1.72
Quick ratio1.66
Total debt/total equity2.11
Total debt/total capital0.674
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.